Faculty Collaboration Database

CTSI Cores Search Research Informatics REDCap

Mehdi H. Hamadani MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center
Member of the Center for International Blood and Marrow Transplant Research (CIBMTR)

Send Message

Request Meeting

View Curriculum Vitae

Publications (384)

Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. (Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B) Br J Haematol 2024 Mar;204(3):887-891 PMID: 38054558 SCOPUS ID: 2-s2.0-85178904872 12/06/2023 1 Citation

Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis. (Kelkar AH, Cliff ERS, Jacobson CA, Abel GA, Dijk SW, Krijkamp EM, Redd R, Zurko JC, Hamadani M, Hunink MGM, Cutler C) Ann Intern Med 2023 Dec;176(12):1625-1637 PMID: 38048587 SCOPUS ID: 2-s2.0-85180537373 12/04/2023 2 Citations

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD Jr, Hamadani M) Transplant Cell Ther 2024 Feb;30(2):131-142 PMID: 37951502 SCOPUS ID: 2-s2.0-85179667722 11/12/2023 1 Citation

Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20⁺ B Cell Lymphoma. (Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V) Transplant Cell Ther 2024 Feb;30(2):241.e1-241.e8 PMID: 37898374 SCOPUS ID: 2-s2.0-85178641224 10/29/2023 1 Citation

PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial. (Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, Ai WZ, Radford J, Solh M, Ardeshna KM, Hess BT, Lunning MA, Zinzani PL, Stathis A, Carlo-Stella C, Lossos IS, Caimi PF, Han S, Yang F, Kuker RA, Moskowitz CH) Clin Cancer Res 2024 Jan 05;30(1):139-149 PMID: 37855688 PMCID: PMC10872617 SCOPUS ID: 2-s2.0-85181760711 10/19/2023 1 Citation

Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study. (Mohan M, Kothari A, Verhagen N, Shreenivas A, Radhakrishnan SV, Dhakal B, Figueroa-Castro C, Chhabra S, Janz S, Pasquini M, Hamadani M, Szabo A, D'Souza A, N3C consortium) Bone Marrow Transplant 2024 Jan;59(1):121-124 PMID: 37803198 SCOPUS ID: 2-s2.0-85173730029 10/07/2023 1 Citation

Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. (Meyers G, Hamadani M, Martens M, Ali H, Chevallier P, Choe H, Harris AC, Holler E, van Hooren E, Klaassen W, Leifer E, van Oosterhout Y, Perez L, Pusic I, Stelljes M, van der Velden W, Ammatuna E, Beauvais D, Cornillon J, Maziarz RT, Schetelig J, Romeril J, MacMillan ML, Levine JE, Socié G) Bone Marrow Transplant 2023 Dec;58(12):1416-1418 PMID: 37749187 SCOPUS ID: 2-s2.0-85172133108 09/26/2023 1 Citation

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. (Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C) Haematologica 2024 Apr 01;109(4):1184-1193 PMID: 37646659 PMCID: PMC10985439 SCOPUS ID: 2-s2.0-85189745390 08/30/2023 5 Citations

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. (Gordon LI, Liu FF, Braverman J, Hoda D, Ghosh N, Hamadani M, Hildebrandt GC, Peng L, Guo S, Shi L, Sehgal A) Haematologica 2024 Mar 01;109(3):857-866 PMID: 37646670 PMCID: PMC10905070 SCOPUS ID: 2-s2.0-85186745211 08/30/2023

Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. (Arshad S, Fang X, Ahn KW, Kaur M, Scordo M, Sauter CS, Furqan F, Awan FT, Hamadani M) Bone Marrow Transplant 2023 Nov;58(11):1203-1208 PMID: 37563283 PMCID: PMC11078515 SCOPUS ID: 2-s2.0-85167505015 08/11/2023 1 Citation

Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. (Hamadani M, Coleman M, Boccia R, Duras J, Hutchings M, Zinzani PL, Cordoba R, Oreiro MB, Williams V, Liu H, Stouffs M, Langmuir P, Sancho JM) Hematol Oncol 2023 Dec;41(5):848-857 PMID: 37496298 SCOPUS ID: 2-s2.0-85165900353 07/27/2023

Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy. (Kanate AS, Majhail N, DeFilipp Z, Dhakal B, Dholaria B, Hamilton B, Herrera AF, Inamoto Y, Jain T, Perales MA, Carpenter PA, Hamadani M) Transplant Cell Ther 2023 Oct;29(10):594-597 PMID: 37422194 SCOPUS ID: 2-s2.0-85166329205 07/09/2023 9 Citations

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. (Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M) Transplant Cell Ther 2023 Sep;29(9):548-555 PMID: 37419325 SCOPUS ID: 2-s2.0-85165977732 07/08/2023 2 Citations

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. (Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators) N Engl J Med 2023 Jun 22;388(25):2338-2348 PMID: 37342922 PMCID: PMC10575613 SCOPUS ID: 2-s2.0-85164529275 06/21/2023 22 Citations

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. (Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA) EClinicalMedicine 2023 May;59:101983 PMID: 37128256 PMCID: PMC10133891 SCOPUS ID: 2-s2.0-85153604229 05/02/2023 10 Citations

Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. (Ahmed N, Mahmoudjafari Z, Hamadani M, Hashmi H) Transplant Cell Ther 2023 Jun;29(6):399-402 PMID: 36990223 SCOPUS ID: 2-s2.0-85153606028 03/30/2023 2 Citations

Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. (Auletta JJ, Kou J, Chen M, Bolon YT, Broglie L, Bupp C, Christianson D, Cusatis RN, Devine SM, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez WS, Phelan R, Riches ML, Rizzo JD, Saber W, Spellman SR, Stefanski HE, Steinert P, Tuschl E, Yusuf R, Zhang MJ, Shaw BE) Transplant Cell Ther 2023 Jun;29(6):346.e1-346.e10 PMID: 36924931 PMCID: PMC10239334 SCOPUS ID: 2-s2.0-85153327578 03/17/2023 12 Citations

Evaluation of Children with Malignancies for Blood and Marrow Transplantation: A Report from the ASTCT Committee on Practice Guidelines. (Fraint E, Abdel-Azim H, Bhatt NS, Broglie L, Chattha A, Kohorst M, Ktena YP, Lee MA, Long S, Qayed M, Sharma A, Stefanski H, Vatsayan A, Wray L, Hamadani M, Carpenter PA) Transplant Cell Ther 2023 May;29(5):293-301 PMID: 36775202 SCOPUS ID: 2-s2.0-85149881881 02/13/2023 1 Citation

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. (Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M) Haematologica 2023 Aug 01;108(8):2249-2254 PMID: 36601982 PMCID: PMC10388259 SCOPUS ID: 2-s2.0-85166385557 01/06/2023 1 Citation

Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. (Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H Sr, Boumendil A Sr, Glass B, Castagna L, Dominietto A, McGuirk J, Blaise D, Gülbas Z, Diez-Martin J, Marsh SGE, Paczesny S, Gadalla SM, Dreger P, Zhang MJ, Spellman SR, Lee SJ, Bolon YT, Sureda A) Transplant Cell Ther 2023 Mar;29(3):184.e1-184.e9 PMID: 36577482 PMCID: PMC10316698 SCOPUS ID: 2-s2.0-85146900314 12/29/2022 5 Citations

Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. (Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG) Mol Ther 2023 Mar 01;31(3):676-685 PMID: 36518079 PMCID: PMC10014221 SCOPUS ID: 2-s2.0-85145741279 12/16/2022 4 Citations

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB) Blood Adv 2023 Jun 13;7(11):2287-2296 PMID: 36516079 PMCID: PMC10225877 SCOPUS ID: 2-s2.0-85162894801 12/15/2022 4 Citations

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. (DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, Atallah E, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE) Transplant Cell Ther 2023 Feb;29(2):71-81 PMID: 36436780 SCOPUS ID: 2-s2.0-85145302399 11/28/2022 13 Citations

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. (Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN) Blood Adv 2023 Jun 13;7(11):2463-2467 PMID: 36417762 PMCID: PMC10241849 SCOPUS ID: 2-s2.0-85179466193 11/24/2022

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study. (Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL) Leuk Lymphoma 2023 Jan;64(1):130-139 PMID: 36398795 SCOPUS ID: 2-s2.0-85142278083 11/19/2022 4 Citations

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. (Toukam M, Wuerthner J, Havenith K, Hamadani M, Caimi PF, Kopotsha T, Cruz HG, Boni JP) Cancer Chemother Pharmacol 2023 Jan;91(1):13-24 PMID: 36333464 SCOPUS ID: 2-s2.0-85141426016 11/06/2022 2 Citations

Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. (Toukam M, Boni JP, Hamadani M, Caimi PF, Cruz HG, Wuerthner J) Cancer Chemother Pharmacol 2023 Jan;91(1):1-12 PMID: 36333463 SCOPUS ID: 2-s2.0-85141403572 11/06/2022 2 Citations

Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Transplant Cell Ther 2022 Oct;28(10):717 PMID: 36202527 SCOPUS ID: 2-s2.0-85101258094 10/07/2022

Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Transplant Cell Ther 2022 Oct;28(10):715-716 PMID: 36202526 SCOPUS ID: 2-s2.0-85108559179 10/07/2022 1 Citation

Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis. (Epperla N, Reljic T, Chowdhury SM, Ferreri AJM, Kumar A, Hamadani M) Hematol Oncol 2023 Feb;41(1):88-96 PMID: 36192141 SCOPUS ID: 2-s2.0-85139404033 10/04/2022 5 Citations

Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma. (Furqan F, Ahn KW, Chen Y, Kaur M, Abutalib SA, Ahmed N, Ahmed S, Kharfan-Dabaja MA, Friedberg J, Gregory T, Hill L, Sterling C, Barta SK, Shadman M, Perales MA, Zain J, Herrera AF, Sauter C, Hamadani M) Br J Haematol 2023 Jan;200(1):54-63 PMID: 36120837 PMCID: PMC9772096 SCOPUS ID: 2-s2.0-85138249429 09/20/2022 2 Citations

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256 PMID: 36106394 PMCID: PMC9827178 SCOPUS ID: 2-s2.0-85145424654 09/16/2022 1 Citation

Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 SCOPUS ID: 2-s2.0-85138335080 09/08/2022 7 Citations

Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas. (Muhsen IN, El Fakih R, Hamadani M, Lazarus HM, Kharfan-Dabaja MA, Aljurf M) Clin Hematol Int 2022 Jun;4(1-2):1-10 PMID: 35950208 PMCID: PMC9358781 SCOPUS ID: 2-s2.0-85145931491 08/12/2022 6 Citations

Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. (Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 Nov;22(11):863-868 PMID: 35934632 SCOPUS ID: 2-s2.0-85135507182 08/08/2022 4 Citations

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. (Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston N, Essell J, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta N, Dubowy R, D'Andrea A, Wang L, Ogasawara K, Thorpe J, Gordon LI) Lancet Oncol 2022 Aug;23(8):1066-1077 PMID: 35839786 SCOPUS ID: 2-s2.0-85135232164 07/16/2022 67 Citations

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. (Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF) Haematologica 2023 Jan 01;108(1):98-109 PMID: 35833303 PMCID: PMC9827150 SCOPUS ID: 2-s2.0-85144275501 07/15/2022 30 Citations

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. (Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF) Blood Adv 2022 Aug 23;6(16):4736-4739 PMID: 35790100 PMCID: PMC9631657 SCOPUS ID: 2-s2.0-85136494015 07/06/2022

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, Shah GL, Svoboda J, Hamadani M) Transplant Cell Ther 2022 Sep;28(9):546-559 PMID: 35768052 PMCID: PMC9427727 SCOPUS ID: 2-s2.0-85135360795 06/30/2022 13 Citations

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. (Ahmed N, Kumar A, Kharfan-Dabaja MA, DeFilipp Z, Herrera A, Hashmi S, Dholaria B, Perales MA, Carpenter PA, Hamadani M) Transplant Cell Ther 2022 Sep;28(9):523-529 PMID: 35671986 SCOPUS ID: 2-s2.0-85133803493 06/08/2022 8 Citations

The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time. (AlYamany R, Kharfan-Dabaja MA, Hamadani M, Alshaibani A, Aljurf M) Curr Oncol 2022 May 23;29(5):3759-3769 PMID: 35621691 PMCID: PMC9139652 SCOPUS ID: 2-s2.0-85130555017 05/28/2022

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. (Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M) Transplant Cell Ther 2022 Aug;28(8):487.e1-487.e7 PMID: 35609865 PMCID: PMC9375438 SCOPUS ID: 2-s2.0-85132887608 05/25/2022 4 Citations

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. (Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C) Blood 2022 Jul 28;140(4):303-308 PMID: 35580172 PMCID: PMC9335500 SCOPUS ID: 2-s2.0-85135069541 05/18/2022 13 Citations

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma. (Hamadani M, Chen L, Song Y, Xu MK, Liao L, Caimi PF, Carlo-Stella C) Clin Lymphoma Myeloma Leuk 2022 Aug;22(8):e738-e744 PMID: 35513980 SCOPUS ID: 2-s2.0-85129561060 05/07/2022 3 Citations

Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. (Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, Horowitz M, Auletta JJ, Shaw BE, Arora M) Transplant Cell Ther 2022 Jul;28(7):409.e1-409.e10 PMID: 35447374 PMCID: PMC9840526 SCOPUS ID: 2-s2.0-85130441260 04/22/2022 25 Citations

Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. (Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, Faisal MS, Hoffmann M, Abdallah AO, Divine C, Hamadani M, McGuirk J, Shune L) Transplant Cell Ther 2022 Jul;28(7):358-364 PMID: 35429662 SCOPUS ID: 2-s2.0-85131127217 04/17/2022 40 Citations

Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. (Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih RE, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge PW, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M) Transplant Cell Ther 2022 Aug;28(8):455-462 PMID: 35413459 SCOPUS ID: 2-s2.0-85132913133 04/13/2022 2 Citations

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. (Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM) Yale J Biol Med 2022 Mar;95(1):45-56 PMID: 35370486 PMCID: PMC8961707 SCOPUS ID: 2-s2.0-85127524780 04/05/2022 2 Citations

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. (Furqan F, Hamadani M) Ther Adv Hematol 2022;13:20406207221087511 PMID: 35340719 PMCID: PMC8943462 SCOPUS ID: 2-s2.0-85126861108 03/29/2022 8 Citations

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. (Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S) Transplant Cell Ther 2022 Jun;28(6):284-293 PMID: 35306217 SCOPUS ID: 2-s2.0-85128352615 03/21/2022 13 Citations

Reality check: Real-world evidence to support therapeutic development in hematologic malignancies. (Derman BA, Belli AJ, Battiwalla M, Hamadani M, Kansagra A, Lazarus HM, Wang CK) Blood Rev 2022 May;53:100913 PMID: 35272867 SCOPUS ID: 2-s2.0-85128229876 03/12/2022 7 Citations

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. (Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN) JAMA Oncol 2022 May 01;8(5):773-775 PMID: 35266965 PMCID: PMC8914887 SCOPUS ID: 2-s2.0-85126591538 03/11/2022 13 Citations

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. (Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M) Cancer Cell 2022 Apr 11;40(4):340-342 PMID: 35202585 PMCID: PMC8864440 SCOPUS ID: 2-s2.0-85127542763 02/25/2022 35 Citations

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. (Mohan M, Nagavally S, Shah N NN, Michaelis L, Chhabra S, Souza AD, Abedin S, Runaas L, Guru Murthy GS, Longo W, Hamadani M, Dhakal B, Hari P, Fenske TS) Clin Lymphoma Myeloma Leuk 2022 Jul;22(7):e495-e497 PMID: 35148976 PMCID: PMC8767926 SCOPUS ID: 2-s2.0-85132179962 02/13/2022 2 Citations

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. (Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF) Haematologica 2022 May 01;107(5):1214-1217 PMID: 35112554 PMCID: PMC9052914 SCOPUS ID: 2-s2.0-85129629839 02/04/2022 5 Citations

Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. (Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M) Br J Haematol 2022 Apr;197(2):212-222 PMID: 35106754 PMCID: PMC9018546 SCOPUS ID: 2-s2.0-85124009986 02/03/2022 6 Citations

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. (Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 May;22(5):e335-e339 PMID: 35034868 SCOPUS ID: 2-s2.0-85122947297 01/18/2022 16 Citations

New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. (Iqbal M, Savani BN, Hamadani M) EJHaem 2022 Jan;3(Suppl 1):11-23 PMID: 34988550 PMCID: PMC8725814 01/07/2022

Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? (Hamadani M) Haematologica 2022 Jul 01;107(7):1500-1502 PMID: 34965703 PMCID: PMC9244808 SCOPUS ID: 2-s2.0-85133321520 12/31/2021

Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. (Hamadani M, Liao L, Yang T, Chen L, Moskowitz C) Clin Lymphoma Myeloma Leuk 2022 Jun;22(6):373-381 PMID: 34933826 SCOPUS ID: 2-s2.0-85121373749 12/23/2021 5 Citations

Loncastuximab tesirine for diffuse large B-cell lymphoma. (Zurko J, Hamadani M) Drugs Today (Barc) 2021 Dec;57(12):733-743 PMID: 34909802 SCOPUS ID: 2-s2.0-85121521473 12/16/2021

Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors. (Epperla N, Hamadani M) Hematology Am Soc Hematol Educ Program 2021 Dec 10;2021(1):247-253 PMID: 34889401 PMCID: PMC8791097 SCOPUS ID: 2-s2.0-85122445074 12/11/2021 3 Citations

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. (Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P) Blood Adv 2022 Feb 08;6(3):920-930 PMID: 34861680 PMCID: PMC8945300 SCOPUS ID: 2-s2.0-85124235616 12/04/2021 16 Citations

Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. (Meyers G, Hamadani M, Martens M, Ali H, Choe H, Dawson P, Harris AC, van Hooren E, Klaassen W, Leifer E, MacMillan ML, van Oosterhout Y, Perez L, Pusic I, Vo P, Levine JE) Bone Marrow Transplant 2022 Feb;57(2):302-303 PMID: 34815518 PMCID: PMC8825705 SCOPUS ID: 2-s2.0-85119658579 11/25/2021 1 Citation

The Impact of Beta-Blocker Use at the Time of Hematopoietic Cell Transplantation on the Development of Acute and Chronic Graft-Versus-Host Disease. (Patel A, Murthy GSG, Hamadani M, Szabo A, Knight JM) Hematol Oncol Stem Cell Ther 2023 Apr 04;16(3):209-216 PMID: 34780786 SCOPUS ID: 2-s2.0-85119520781 11/16/2021

Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. (Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N) Hematol Oncol 2022 Feb;40(1):48-56 PMID: 34763367 SCOPUS ID: 2-s2.0-85119403860 11/12/2021 2 Citations

Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. (Dhakal B, Chhabra S, Savani BN, Hamadani M) Br J Haematol 2022 Apr;197(1):28-40 PMID: 34671973 SCOPUS ID: 2-s2.0-85117396384 10/22/2021 7 Citations

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. (Hamadani M, Gopal AK, Pasquini M, Kim S, Qiu X, Ahmed S, Lazaryan A, Bhatt VR, Daly A, Lulla P, Ciurea S, Gauthier J, Agrawal V, Grover NS, Lekakis L, Modi D, Dahi PB, Herr MM, Johnson PC, Hashmi H, Hematti P, Locke FL) Blood Adv 2022 Jan 25;6(2):486-494 PMID: 34673903 PMCID: PMC8791562 SCOPUS ID: 2-s2.0-85123544420 10/22/2021 24 Citations

Epidemiology of Food Insecurity in a Nationally Representative Sample of Lymphoma Patients. (Jella T, Cwalina TB, Hamadani M) Clin Lymphoma Myeloma Leuk 2022 Feb;22(2):e128-e134 PMID: 34615618 SCOPUS ID: 2-s2.0-85116353445 10/08/2021 6 Citations

Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. (Ahmed N, Hamadani M) Expert Rev Anticancer Ther 2021 Dec;21(12):1313-1320 PMID: 34597242 SCOPUS ID: 2-s2.0-85117853842 10/02/2021 1 Citation

Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. (Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM) Br J Haematol 2021 Dec;195(5):757-763 PMID: 34581433 PMCID: PMC8627449 SCOPUS ID: 2-s2.0-85115835960 09/29/2021 3 Citations

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. (Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi PN, Beitinjaneh A, Reagan PM, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M) Blood 2022 Mar 03;139(9):1330-1339 PMID: 34570879 PMCID: PMC8900276 SCOPUS ID: 2-s2.0-85125439632 09/28/2021 49 Citations

CAR T-cell therapy for secondary CNS DLBCL. (Ahmed G, Hamadani M, Shah NN) Blood Adv 2021 Dec 28;5(24):5626-5630 PMID: 34551065 PMCID: PMC8714710 SCOPUS ID: 2-s2.0-85122300713 09/23/2021 40 Citations

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. (Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB) Blood Adv 2021 Dec 14;5(23):5179-5189 PMID: 34516611 PMCID: PMC9153047 SCOPUS ID: 2-s2.0-85120335416 09/14/2021 22 Citations

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. (Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M) Blood Adv 2021 Sep 28;5(18):3528-3539 PMID: 34496026 PMCID: PMC8945575 SCOPUS ID: 2-s2.0-85116143497 09/09/2021 22 Citations

Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. (Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, Horowitz MM) Transplant Cell Ther 2021 Nov;27(11):885-907 PMID: 34461278 PMCID: PMC8556300 SCOPUS ID: 2-s2.0-85116810681 08/31/2021 11 Citations

American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. (Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS) Transplant Cell Ther 2021 Sep;27(9):720-728 PMID: 34452722 PMCID: PMC8447221 SCOPUS ID: 2-s2.0-85115347371 08/29/2021 9 Citations

Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. (Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, Brunstein CG, Merryman RW, Stiff PJ, Pawarode A, Nishihori T, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM) Transplant Cell Ther 2021 Nov;27(11):911.e1-911.e7 PMID: 34450333 PMCID: PMC8556305 SCOPUS ID: 2-s2.0-85116436482 08/28/2021 6 Citations

ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. (Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS) Bone Marrow Transplant 2021 Dec;56(12):2911-2921 PMID: 34413469 PMCID: PMC8639670 SCOPUS ID: 2-s2.0-85113212083 08/21/2021 20 Citations

The Impact of Post-Hematopoietic Stem Cell Transplant Tyrosine Kinase Inhibitors in Philadelphia-Positive Acute Lymphoblastic Leukemia. (Halahleh K, Al Rimawi D, Abu Ghosh A, Muradi I, Da'na W, Hamadani M) Hematol Oncol Stem Cell Ther 2022 Dec 23;15(4):219-222 PMID: 34352199 SCOPUS ID: 2-s2.0-85113165569 08/06/2021 1 Citation

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. (Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M) Blood 2021 Oct 07;138(14):1278-1281 PMID: 34339501 PMCID: PMC8332674 SCOPUS ID: 2-s2.0-85114112109 08/03/2021 94 Citations

Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. (Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB) Am J Hematol 2021 Nov 01;96(11):1374-1384 PMID: 34324220 PMCID: PMC8511300 SCOPUS ID: 2-s2.0-85112036913 07/30/2021 13 Citations

Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. (Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PA) Transplant Cell Ther 2021 Aug;27(8):642-649 PMID: 34304802 SCOPUS ID: 2-s2.0-85111026486 07/27/2021 67 Citations

Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. (Abboud R, Wan F, Mariotti J, Arango M, Castagna L, Romee R, Hamadani M, Chhabra S) Bone Marrow Transplant 2021 Nov;56(11):2763-2770 PMID: 34262142 SCOPUS ID: 2-s2.0-85118450650 07/16/2021 24 Citations

Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Oct;21(10):e775-e781 PMID: 34257042 SCOPUS ID: 2-s2.0-85110347842 07/15/2021

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. (Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M) Br J Haematol 2021 Nov;195(3):429-432 PMID: 34254289 PMCID: PMC9293486 SCOPUS ID: 2-s2.0-85109689194 07/14/2021 5 Citations

Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. (Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D) Leukemia 2021 Jul;35(7):2140 PMID: 34088982 PMCID: PMC8329698 SCOPUS ID: 2-s2.0-85107597501 06/06/2021 1 Citation

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. (Hamadani M, Collins GP, Caimi PF, Samaniego F, Spira A, Davies A, Radford J, Menne T, Karnad A, Zain JM, Fields P, Havenith K, Cruz HG, He S, Boni J, Feingold J, Wuerthner J, Horwitz S) Lancet Haematol 2021 Jun;8(6):e433-e445 PMID: 34048682 PMCID: PMC9241579 SCOPUS ID: 2-s2.0-85106530441 05/29/2021 49 Citations

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. (Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS) JCO Precis Oncol 2021;5 PMID: 34036237 PMCID: PMC8140814 SCOPUS ID: 2-s2.0-85105451387 05/27/2021 19 Citations

Enteropathy-Associated T cell Lymphoma. (Al Somali Z, Hamadani M, Kharfan-Dabaja M, Sureda A, El Fakih R, Aljurf M) Curr Hematol Malig Rep 2021 Apr;16(2):140-147 PMID: 34009525 SCOPUS ID: 2-s2.0-85106222213 05/20/2021 15 Citations

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. (Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C) Lancet Oncol 2021 Jun;22(6):790-800 PMID: 33989558 SCOPUS ID: 2-s2.0-85107129023 05/15/2021 217 Citations

Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. (Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, Fenske TS, Malecek M, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB) Eur J Haematol 2021 Sep;107(3):301-310 PMID: 33973276 PMCID: PMC8338766 SCOPUS ID: 2-s2.0-85108117542 05/12/2021 3 Citations

Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. (Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ) Transplant Cell Ther 2021 May;27(5):380-388 PMID: 33965174 PMCID: PMC8415092 SCOPUS ID: 2-s2.0-85101079037 05/10/2021 4 Citations

Cellular Therapies for Mantle Cell Lymphoma. (Yassine F, Sandoval-Sus J, Ayala E, Chavez J, Hamadani M, Kharfan-Dabaja MA) Transplant Cell Ther 2021 May;27(5):363-370 PMID: 33965173 SCOPUS ID: 2-s2.0-85101829198 05/10/2021 4 Citations

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. (Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS) JAMA Oncol 2021 Jul 01;7(7):993-1003 PMID: 33956047 PMCID: PMC8283558 SCOPUS ID: 2-s2.0-85105866863 05/07/2021 43 Citations

Correction: Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. (Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ) Bone Marrow Transplant 2021 Jun;56(6):1486 PMID: 33941873 SCOPUS ID: 2-s2.0-85105183322 05/05/2021 1 Citation

Correction: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2021 Apr 29;11(4):82 PMID: 33927193 PMCID: PMC8085088 SCOPUS ID: 2-s2.0-85105142269 05/01/2021

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. (Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D) Leukemia 2021 Jul;35(7):2076-2085 PMID: 33785862 PMCID: PMC8257494 SCOPUS ID: 2-s2.0-85103388621 04/01/2021 25 Citations

Risk Factors for Cost-Related Delays to Medical Care Among Lymphoma Patients: A 22-Year Analysis of a Nationally Representative Sample. (Jella TK, Cwalina TB, Treisman J, Hamadani M) Clin Lymphoma Myeloma Leuk 2021 Jul;21(7):e619-e625 PMID: 33785298 SCOPUS ID: 2-s2.0-85106233500 04/01/2021 5 Citations

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. (Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME) Transplant Cell Ther 2021 Jun;27(6):483.e1-483.e6 PMID: 33775615 PMCID: PMC8217373 SCOPUS ID: 2-s2.0-85106302930 03/30/2021 57 Citations

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. (Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C) Leukemia 2021 Sep;35(9):2672-2683 PMID: 33658659 SCOPUS ID: 2-s2.0-85102037379 03/05/2021 47 Citations

Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. (Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ) Bone Marrow Transplant 2021 Apr;56(4):786-797 PMID: 33514917 PMCID: PMC8168056 SCOPUS ID: 2-s2.0-85099909157 01/31/2021 5 Citations

A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine. (Epperla N, Hamadani M) Curr Hematol Malig Rep 2021 Feb;16(1):19-24 PMID: 33492560 SCOPUS ID: 2-s2.0-85099970847 01/26/2021 5 Citations

Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? (Shah NN, Hamadani M) J Clin Oncol 2021 Feb 10;39(5):487-498 PMID: 33434076 SCOPUS ID: 2-s2.0-85102044262 01/13/2021 24 Citations

Breast Implant-associated Anaplastic Large Cell Lymphoma. (Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M) Clin Lymphoma Myeloma Leuk 2021 Mar;21(3):e272-e276 PMID: 33384263 SCOPUS ID: 2-s2.0-85098512838 01/02/2021 7 Citations

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. (Abedin S, Hamadani M) J Exp Pharmacol 2020;12:549-557 PMID: 33273867 PMCID: PMC7705269 SCOPUS ID: 2-s2.0-85097884873 12/05/2020 8 Citations

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. (Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS) Blood 2021 May 13;137(19):2634-2645 PMID: 33211842 PMCID: PMC8138546 SCOPUS ID: 2-s2.0-85106521180 11/20/2020 102 Citations

Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply. (Hamadani M, Litovich C, Ahn KW) JAMA Oncol 2020 Dec 01;6(12):1984 PMID: 33151256 SCOPUS ID: 2-s2.0-85095867531 11/06/2020 1 Citation

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? (Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M) Blood 2021 Mar 11;137(10):1416-1423 PMID: 33120429 PMCID: PMC7955408 SCOPUS ID: 2-s2.0-85102604135 10/30/2020 47 Citations

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. (Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M) Hematol Oncol Stem Cell Ther 2021 Mar;14(1):65-70 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020 13 Citations

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020 263 Citations

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. (Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A) Transplant Cell Ther 2021 Jan;27(1):6-20 PMID: 32966881 SCOPUS ID: 2-s2.0-85092464789 09/24/2020 40 Citations

Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. (Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M) Transplant Cell Ther 2021 Jan;27(1):58-66 PMID: 32956819 PMCID: PMC7972998 SCOPUS ID: 2-s2.0-85093981145 09/22/2020 18 Citations

Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. (Bal S, Costa LJ, Sauter C, Litovich C, Hamadani M) Transplant Cell Ther 2021 Jan;27(1):55.e1-55.e7 PMID: 32949754 PMCID: PMC7965782 SCOPUS ID: 2-s2.0-85092608602 09/20/2020 10 Citations

Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. (Monahan K, Kleman A, Thapa B, Szabo A, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Hamadani M, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2020 Dec;26(12):2229-2236 PMID: 32920204 SCOPUS ID: 2-s2.0-85092250990 09/14/2020 3 Citations

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. (Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M) Blood Adv 2020 Aug 25;4(16):3850-3852 PMID: 32797191 PMCID: PMC7448593 SCOPUS ID: 2-s2.0-85096132028 08/17/2020 40 Citations

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. (Badar T, Johnson BD, Hamadani M) Bone Marrow Transplant 2021 Mar;56(3):683-685 PMID: 32782349 SCOPUS ID: 2-s2.0-85089247553 08/13/2020 7 Citations

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. (Dhakal B, Hari PN, Usmani SZ, Hamadani M) Bone Marrow Transplant 2021 Jan;56(1):9-19 PMID: 32770147 SCOPUS ID: 2-s2.0-85089253834 08/10/2020 23 Citations

Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. (Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Nov;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020 12 Citations

Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. (Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee) Biol Blood Marrow Transplant 2020 Dec;26(12):2181-2189 PMID: 32717432 PMCID: PMC7380217 SCOPUS ID: 2-s2.0-85089451061 07/28/2020 48 Citations

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W) Blood Adv 2020 Jul 14;4(13):3180-3190 PMID: 32663298 PMCID: PMC7362362 SCOPUS ID: 2-s2.0-85088320644 07/15/2020 17 Citations

Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Oct;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020 4 Citations

Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020 18 Citations

Trends in the use of therapeutic plasma exchange in multiple myeloma. (Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P) J Clin Apher 2020 Aug;35(4):307-315 PMID: 32516865 SCOPUS ID: 2-s2.0-85086092696 06/10/2020 3 Citations

Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. (Ghosh N, Ahmed S, Ahn KW, Khanal M, Litovich C, Aljurf M, Bacher VU, Bredeson C, Epperla N, Farhadfar N, Freytes CO, Ganguly S, Haverkos B, Inwards D, Kamble RT, Lazarus HM, Lekakis L, Murthy HS, Nishihori T, Ramakrishnan P, Rizzieri DA, Yared JA, Kharfan-Dabaja MA, Sureda A, Hamadani M) JAMA Oncol 2020 Jul 01;6(7):1011-1018 PMID: 32496525 PMCID: PMC7273311 SCOPUS ID: 2-s2.0-85086233103 06/05/2020 36 Citations

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. (D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, Horowitz MM) Biol Blood Marrow Transplant 2020 Aug;26(8):e177-e182 PMID: 32438042 PMCID: PMC7404814 SCOPUS ID: 2-s2.0-85085969206 05/22/2020 317 Citations

Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. (Badar T, Astle J, Kakar IK, Zellner K, Hari PN, Hamadani M) Br J Haematol 2020 Jul;190(2):e98-e101 PMID: 32415780 SCOPUS ID: 2-s2.0-85084830591 05/18/2020 9 Citations

Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. (Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, Horowitz MM) Biol Blood Marrow Transplant 2020 Jul;26(7):e161-e166 PMID: 32389803 PMCID: PMC7206419 SCOPUS ID: 2-s2.0-85084668943 05/12/2020 38 Citations

Eligibility Criteria for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. (Kanate AS, Perales MA, Hamadani M) J Natl Compr Canc Netw 2020 May;18(5):635-643 PMID: 32380457 SCOPUS ID: 2-s2.0-85084408283 05/08/2020 8 Citations

Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. (Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M) Br J Haematol 2020 Aug;190(4):573-582 PMID: 32314807 PMCID: PMC7575614 SCOPUS ID: 2-s2.0-85083643436 04/22/2020 16 Citations

Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. (Abedin SM, Hamadani M) Expert Opin Investig Drugs 2020 May;29(5):423-427 PMID: 32293938 SCOPUS ID: 2-s2.0-85083651597 04/16/2020 7 Citations

Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. (Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM) Biol Blood Marrow Transplant 2020 Jul;26(7):1312-1317 PMID: 32283185 PMCID: PMC7194895 SCOPUS ID: 2-s2.0-85083795044 04/14/2020 49 Citations

Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis. (Rashidi A, Meybodi MA, Cao W, Chu H, Warlick ED, Devine S, Pasquini MC, Weisdorf DJ, Hamadani M) Biol Blood Marrow Transplant 2020 Jun;26(6):e138-e141 PMID: 32171885 SCOPUS ID: 2-s2.0-85083504564 03/17/2020 8 Citations

Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. (Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, Fenske TS, Sauter C, Kharfan-Dabaja MA, Awan FT) Biol Blood Marrow Transplant 2020 Jun;26(6):1099-1105 PMID: 32165327 PMCID: PMC7255948 SCOPUS ID: 2-s2.0-85083523089 03/14/2020 7 Citations

Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. (Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani M) Biol Blood Marrow Transplant 2020 Jul;26(7):1247-1256 PMID: 32165328 SCOPUS ID: 2-s2.0-85084227379 03/14/2020 129 Citations

Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. (Dhakal B, Narra RK, Giri S, Szabo A, Smunt TL, Ghose S, Pathak LK, Aryal M, Hamadani M, Chhabra S, Janz S, D'Souza A, Hari PN) Cancer 2020 Jun 15;126(12):2791-2801 PMID: 32154922 SCOPUS ID: 2-s2.0-85081273628 03/11/2020 5 Citations

Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. (Chhabra S, Szabo A, Glisch C, George G, Narra RK, Harrington A, Jerkins JH, D'Souza A, Dhakal B, Pasquini MC, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 Jul;26(7):1288-1297 PMID: 32135202 SCOPUS ID: 2-s2.0-85083636589 03/07/2020 10 Citations

Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. (Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M) Cancer 2020 May 15;126(10):2279-2287 PMID: 32049359 PMCID: PMC7190439 SCOPUS ID: 2-s2.0-85079369077 02/13/2020 16 Citations

Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. (Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M) J Clin Oncol 2020 May 10;38(14):1518-1526 PMID: 32031876 PMCID: PMC7213591 SCOPUS ID: 2-s2.0-85084380128 02/08/2020 31 Citations

Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 Feb 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020 37 Citations

Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020 12 Citations

Cellular Immunotherapy for Refractory Diffuse Large B Cell Lymphoma in the Chimeric Antigen Receptor-Engineered T Cell Era: Still a Role for Allogeneic Transplantation? (Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M, European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)) Biol Blood Marrow Transplant 2020 Apr;26(4):e77-e85 PMID: 31917272 PMCID: PMC7207150 SCOPUS ID: 2-s2.0-85079050617 01/10/2020 40 Citations

Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. (Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS) Blood Adv 2020 Jan 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020 20 Citations

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. (Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME) J Clin Oncol 2020 Apr 20;38(12):1273-1283 PMID: 31860405 PMCID: PMC7164487 SCOPUS ID: 2-s2.0-85083545151 12/21/2019 268 Citations

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2019 Dec 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019 11 Citations

Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. (Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M) Leuk Lymphoma 2020 Apr;61(4):869-874 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019 17 Citations

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML) Blood 2020 Jan 09;135(2):97-107 PMID: 31738834 PMCID: PMC6952830 SCOPUS ID: 2-s2.0-85077761109 11/19/2019 55 Citations

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. (Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA) Clin Cancer Res 2019 Dec 01;25(23):6986-6994 PMID: 31685491 SCOPUS ID: 2-s2.0-85075960499 11/07/2019 71 Citations

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. (DeFilipp Z, Ancheta R, Liu Y, Hu ZH, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn JY, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W) Biol Blood Marrow Transplant 2020 Mar;26(3):472-479 PMID: 31669399 PMCID: PMC7358778 SCOPUS ID: 2-s2.0-85076548681 11/02/2019 23 Citations

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. (Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M) Blood Adv 2019 Oct 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019 36 Citations

An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis. (Badar T, Dhakal B, Szabo A, Padmanabhan A, Johnson BD, Heidtke S, Esselmann J, Chhabra S, Hamadani M, Hari P, D'Souza A) J Clin Apher 2019 Dec;34(6):686-691 PMID: 31566813 PMCID: PMC6957224 SCOPUS ID: 2-s2.0-85073930913 10/01/2019 2 Citations

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. (Meybodi MA, Cao W, Luznik L, Bashey A, Zhang X, Romee R, Saber W, Hamadani M, Weisdorf DJ, Chu H, Rashidi A) Blood Adv 2019 Sep 10;3(17):2581-2585 PMID: 31484635 PMCID: PMC6737418 SCOPUS ID: 2-s2.0-85072206849 09/06/2019 23 Citations

Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN) Oncologist 2019 Nov;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019 6 Citations

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. (Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, Horowitz M, Niederwieser D) Hematol Oncol Stem Cell Ther 2020 Mar;13(1):7-16 PMID: 31449781 SCOPUS ID: 2-s2.0-85080069497 08/27/2019 12 Citations

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y) Biol Blood Marrow Transplant 2019 Dec;25(12):2305-2321 PMID: 31446199 SCOPUS ID: 2-s2.0-85072519127 08/26/2019 129 Citations

Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. (Epperla N, Hamadani M, Reljic T, Kharfan-Dabaja MA, Savani BN, Kumar A) Cancer 2019 Dec 15;125(24):4417-4425 PMID: 31441943 SCOPUS ID: 2-s2.0-85070946641 08/24/2019 17 Citations

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 Jul 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019 16 Citations

Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019 2 Citations

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant. (Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P) Biol Blood Marrow Transplant 2019 Oct;25(10):e305-e309 PMID: 31295572 SCOPUS ID: 2-s2.0-85072992270 07/12/2019 2 Citations

Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 Jul 03;2(7):e196476 PMID: 31276175 SCOPUS ID: 2-s2.0-85068511187 07/06/2019 11 Citations

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. (Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR) Clin Cancer Res 2019 Aug 15;25(16):5143-5155 PMID: 31253630 PMCID: PMC6697588 SCOPUS ID: 2-s2.0-85070674030 06/30/2019 11 Citations

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. (Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W) Blood Adv 2019 Jun 25;3(12):1826-1836 PMID: 31201170 PMCID: PMC6595262 SCOPUS ID: 2-s2.0-85068734856 06/16/2019 83 Citations

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. (Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS) Blood Adv 2019 Jun 11;3(11):1661-1669 PMID: 31167818 PMCID: PMC6560348 SCOPUS ID: 2-s2.0-85067501987 06/07/2019 22 Citations

Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. (Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M) Biol Blood Marrow Transplant 2019 Sep;25(9):1859-1868 PMID: 31132455 PMCID: PMC6755039 SCOPUS ID: 2-s2.0-85067280149 05/28/2019 56 Citations

FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? (Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network) J Clin Oncol 2019 Jul 01;37(19):1604-1607 PMID: 31034300 PMCID: PMC6804888 SCOPUS ID: 2-s2.0-85068884815 04/30/2019 25 Citations

Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. (Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D) Biol Blood Marrow Transplant 2019 Dec;25(12):2330-2337 PMID: 31002990 SCOPUS ID: 2-s2.0-85065760511 04/20/2019 16 Citations

Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019 67 Citations

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 Aug;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019 21 Citations

Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. (Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM) Blood Adv 2019 Mar 26;3(6):875-883 PMID: 30890544 PMCID: PMC6436017 SCOPUS ID: 2-s2.0-85072746485 03/21/2019 26 Citations

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. (Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S) Biol Blood Marrow Transplant 2019 Jul;25(7):1456-1464 PMID: 30878605 SCOPUS ID: 2-s2.0-85064323899 03/18/2019 16 Citations

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT. (Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M) JAMA Oncol 2019 May 01;5(5):715-722 PMID: 30816957 PMCID: PMC6988125 SCOPUS ID: 2-s2.0-85062339450 03/01/2019 43 Citations

PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. (Dreger P, Sureda A, Ahn KW, Eapen M, Litovich C, Finel H, Boumendil A, Gopal A, Herrera AF, Schmid C, Diez-Martin JL, Fuchs E, Bolaños-Meade J, Gooptu M, Al Malki MM, Castagna L, Ciurea SO, Dominietto A, Blaise D, Ciceri F, Tischer J, Corradini P, Montoto S, Robinson S, Gülbas Z, Hamadani M) Blood Adv 2019 Feb 12;3(3):360-369 PMID: 30723110 PMCID: PMC6373757 SCOPUS ID: 2-s2.0-85061139017 02/07/2019 87 Citations

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG) Leukemia 2019 Jul;33(7):1736-1746 PMID: 30696949 PMCID: PMC6755968 SCOPUS ID: 2-s2.0-85060937214 01/31/2019 39 Citations

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M) J Hematol Oncol 2019 Jan 10;12(1):6 PMID: 30630534 PMCID: PMC6329157 SCOPUS ID: 2-s2.0-85059829766 01/12/2019 28 Citations

Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. (Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N) Clin Lymphoma Myeloma Leuk 2019 Feb;19(2):95-102 PMID: 30581160 SCOPUS ID: 2-s2.0-85058679508 12/26/2018 9 Citations

Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 Apr;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018 22 Citations

Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. (Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA) Bone Marrow Transplant 2019 Jul;54(7):1094-1106 PMID: 30446739 SCOPUS ID: 2-s2.0-85056763634 11/18/2018 31 Citations

Advances in Transplantation for Lymphomas Resulting from CIBMTR Lymphoma Working Committee's Research Portfolio: A Five-Year Report (2013-2018). (Hamadani M) Adv Cell Gene Ther 2018 Nov;1(3) PMID: 33709060 PMCID: PMC7946113 11/01/2018

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. (Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ) Leuk Lymphoma 2019 Apr;60(4):940-946 PMID: 30277110 SCOPUS ID: 2-s2.0-85054414534 10/03/2018 2 Citations

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 Jan;25(1):e33-e38 PMID: 30244105 SCOPUS ID: 2-s2.0-85055445894 09/24/2018 10 Citations

Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma. (Hashmi H, Hamadani M, Awan FT) Expert Opin Pharmacother 2018 Oct;19(15):1631-1634 PMID: 30200789 SCOPUS ID: 2-s2.0-85053325343 09/12/2018 1 Citation

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. (Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, Battiwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Cahn JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayashi RJ, Hematti P, Inamoto Y, Khera N, Kindwall-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wirk B, Yared JA, Aljurf M, Abidi MH, Allewelt H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S, Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK) Leuk Res 2018 Nov;74:130-136 PMID: 30055822 PMCID: PMC6219911 SCOPUS ID: 2-s2.0-85050340275 07/30/2018 40 Citations

Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018 23 Citations

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. (Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB) Leuk Lymphoma 2018 Dec;59(12):2862-2870 PMID: 29912594 PMCID: PMC6360945 SCOPUS ID: 2-s2.0-85048791473 06/19/2018 11 Citations

Reply to the persistent uncertainty of when to recommend allogeneic stem cell transplantation in follicular iymphoma. (Sureda A, Montoto S, Dreger P, Hamadani M, Pasquini MC) Cancer 2018 Aug;124(16):3455-3456 PMID: 29878309 SCOPUS ID: 2-s2.0-85052190185 06/08/2018

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018 28 Citations

Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 Aug;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018 8 Citations

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. (D'Souza A, Flynn K, Chhabra S, Dhakal B, Hamadani M, Jacobsen K, Pasquini M, Weihrauch D, Hari P) Contemp Clin Trials Commun 2017 Dec;8:33-38 PMID: 29696194 PMCID: PMC5898504 SCOPUS ID: 2-s2.0-85027981960 04/27/2018 15 Citations

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. (Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M) Blood Adv 2018 Apr 24;2(8):933-940 PMID: 29685953 PMCID: PMC5916010 SCOPUS ID: 2-s2.0-85055419410 04/25/2018 24 Citations

Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 Aug;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018 31 Citations

Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 Sep;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018 7 Citations

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. (Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M) Cancer 2018 Jun 15;124(12):2541-2551 PMID: 29645093 PMCID: PMC5990449 SCOPUS ID: 2-s2.0-85045242474 04/13/2018 51 Citations

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. (Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA) Biol Blood Marrow Transplant 2018 Jun;24(6):1119-1124 PMID: 29608957 SCOPUS ID: 2-s2.0-85046667868 04/03/2018 30 Citations

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. (Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB) Cancer 2018 Jun 01;124(11):2306-2315 PMID: 29579328 PMCID: PMC5992038 SCOPUS ID: 2-s2.0-85044426982 03/27/2018 39 Citations

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. (Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ) Lancet Haematol 2018 Apr;5(4):e170-e180 PMID: 29550382 PMCID: PMC7029813 SCOPUS ID: 2-s2.0-85043518549 03/20/2018 44 Citations

What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. (Shah NN, Fenske TS, Hamadani M, Svoboda J) Br J Haematol 2019 Mar;184(5):838-840 PMID: 29528099 SCOPUS ID: 2-s2.0-85043472454 03/13/2018

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. (McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, Solh M, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M) Blood Adv 2018 Feb 13;2(3):299-307 PMID: 29440002 PMCID: PMC5812334 SCOPUS ID: 2-s2.0-85050645336 02/15/2018 65 Citations

Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. (Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC) Cancer 2018 Apr 15;124(8):1733-1742 PMID: 29424927 PMCID: PMC5946312 SCOPUS ID: 2-s2.0-85041530897 02/10/2018 50 Citations

Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. (Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V) Biol Blood Marrow Transplant 2018 May;24(5):983-988 PMID: 29410340 SCOPUS ID: 2-s2.0-85042234569 02/08/2018 4 Citations

Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. (Costa LJ, Landau HJ, Chhabra S, Hari P, Innis-Shelton R, Godby KN, Hamadani M, Tamari R, Anderton K, Dixon P, Giralt SA) Biol Blood Marrow Transplant 2018 Jul;24(7):1379-1385 PMID: 29410301 PMCID: PMC7590532 SCOPUS ID: 2-s2.0-85046706138 02/08/2018 16 Citations

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 Apr;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018 36 Citations

Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. (Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE) Bone Marrow Transplant 2018 May;53(5):535-555 PMID: 29343837 PMCID: PMC5985976 SCOPUS ID: 2-s2.0-85040684681 01/19/2018 72 Citations

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. (Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN) JAMA Oncol 2018 Mar 01;4(3):343-350 PMID: 29302684 PMCID: PMC5885822 SCOPUS ID: 2-s2.0-85045789349 01/06/2018 115 Citations

R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. (Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J) Br J Haematol 2018 Feb;180(4):534-544 PMID: 29265182 SCOPUS ID: 2-s2.0-85038422379 12/22/2017 69 Citations

The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. (Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N) Int Rev Immunol 2018 May 04;37(3):165-173 PMID: 29257907 SCOPUS ID: 2-s2.0-85046853040 12/20/2017 3 Citations

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. (Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M) Biol Blood Marrow Transplant 2018 Jun;24(6):1163-1171 PMID: 29242111 PMCID: PMC5993598 SCOPUS ID: 2-s2.0-85040541734 12/16/2017 97 Citations

Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? (Hamadani M, Horowitz MM) J Oncol Pract 2017 Dec;13(12):798-806 PMID: 29232542 PMCID: PMC5728364 SCOPUS ID: 2-s2.0-85039968023 12/13/2017 9 Citations

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. (Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, Fenske TS, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi PF, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Shah B, Chavez JC, Al Malki M, Kumar A, Ganguly S) Biol Blood Marrow Transplant 2018 Mar;24(3):486-493 PMID: 29225164 SCOPUS ID: 2-s2.0-85044870952 12/12/2017 4 Citations

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. (Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P) Cancer 2018 Feb 15;124(4):816-825 PMID: 29125192 PMCID: PMC5871233 SCOPUS ID: 2-s2.0-85033592450 11/11/2017 44 Citations

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). (Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P) J Hematol Oncol 2017 Nov 02;10(1):171 PMID: 29096668 PMCID: PMC5668956 SCOPUS ID: 2-s2.0-85032741408 11/04/2017 33 Citations

Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. (Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P) Biol Blood Marrow Transplant 2018 Mar;24(3):478-485 PMID: 29079457 PMCID: PMC5826888 SCOPUS ID: 2-s2.0-85035213070 10/29/2017 29 Citations

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 Jan;24(1):78-85 PMID: 29032272 PMCID: PMC5743624 SCOPUS ID: 2-s2.0-85034849252 10/17/2017 8 Citations

Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. (Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S) Br J Haematol 2017 Dec;179(5):781-789 PMID: 28980314 SCOPUS ID: 2-s2.0-85035114874 10/06/2017 56 Citations

Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. (Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE) Biol Blood Marrow Transplant 2018 Feb;24(2):228-241 PMID: 28939455 PMCID: PMC5768142 SCOPUS ID: 2-s2.0-85034852162 09/25/2017 44 Citations

Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. (Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB) Transfusion 2017 Nov;57(11):2775-2781 PMID: 28836275 SCOPUS ID: 2-s2.0-85032922198 08/25/2017 24 Citations

Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. (Hammons L, Brazauskas R, Pasquini M, Hamadani M, Hari P, D'Souza A) Hematol Oncol Stem Cell Ther 2018 Jun;11(2):105-111 PMID: 28830801 SCOPUS ID: 2-s2.0-85027963716 08/24/2017 7 Citations

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN) Biol Blood Marrow Transplant 2017 Nov;23(11):1826-1838 PMID: 28797780 SCOPUS ID: 2-s2.0-85030979951 08/12/2017 118 Citations

Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. (Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M) Br J Haematol 2018 Sep;182(6):916-920 PMID: 28771676 PMCID: PMC5796874 SCOPUS ID: 2-s2.0-85026730456 08/05/2017 56 Citations

Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 SCOPUS ID: 2-s2.0-85028446880 08/02/2017 19 Citations

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. (Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2017 Jul;17(7):408-414 PMID: 28756899 SCOPUS ID: 2-s2.0-85026407137 08/02/2017 8 Citations

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. (Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P) Haematologica 2017 Oct;102(10):1767-1775 PMID: 28751562 PMCID: PMC5622861 SCOPUS ID: 2-s2.0-85030316883 07/29/2017 46 Citations

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. (Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evens AM, Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ) Cancer 2017 Nov 15;123(22):4411-4418 PMID: 28749548 SCOPUS ID: 2-s2.0-85026327949 07/28/2017 20 Citations

Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 SCOPUS ID: 2-s2.0-85026445343 07/13/2017 7 Citations

Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. (D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P) Leukemia 2017 Sep;31(9):1998-2000 PMID: 28663578 PMCID: PMC5587375 SCOPUS ID: 2-s2.0-85028872119 07/01/2017 13 Citations

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. (Bashey A, Zhang MJ, McCurdy SR, St Martin A, Argall T, Anasetti C, Ciurea SO, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki MM, Nakamura R, O'Donnell PV, Perales MA, Raj K, Romee R, Rowley S, Rocha V, Salit RB, Solh M, Soiffer RJ, Fuchs EJ, Eapen M) J Clin Oncol 2017 Sep 10;35(26):3002-3009 PMID: 28644773 PMCID: PMC5590802 SCOPUS ID: 2-s2.0-85029169856 06/24/2017 229 Citations

Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances. (Epperla N, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Dec;10(4):277-284 PMID: 28633038 SCOPUS ID: 2-s2.0-85021090462 06/21/2017 27 Citations

Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017 4 Citations

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 Jun 12;10(1):117 PMID: 28606176 PMCID: PMC5469142 SCOPUS ID: 2-s2.0-85020468882 06/14/2017 18 Citations

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 SCOPUS ID: 2-s2.0-85023768076 05/05/2017 197 Citations

Incidence and survival trends in mantle cell lymphoma. (Epperla N, Hamadani M, Fenske TS, Costa LJ) Br J Haematol 2018 Jun;181(5):703-706 PMID: 28444739 SCOPUS ID: 2-s2.0-85018247547 04/27/2017 48 Citations

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017 8 Citations

Systemic Anaplastic Lymphoma Kinase-positive Anaplastic Large Cell Lymphoma: A Population-based Analysis of Incidence and Survival. (Guru Murthy GS, Hamadani M, Bhatt VR, Dhakal I, Mehta P) Clin Lymphoma Myeloma Leuk 2017 Apr;17(4):201-206 PMID: 28395812 SCOPUS ID: 2-s2.0-85017190298 04/12/2017 10 Citations

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME) J Clin Oncol 2017 Apr 10;35(11):1154-1161 PMID: 28380315 PMCID: PMC5455603 SCOPUS ID: 2-s2.0-85017300040 04/06/2017 467 Citations

Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? (Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M) Bone Marrow Transplant 2017 Nov;52(11):1487-1494 PMID: 28368373 SCOPUS ID: 2-s2.0-85016957307 04/04/2017 17 Citations

Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. (Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P) Biol Blood Marrow Transplant 2017 Jun;23(6):952-957 PMID: 28288949 SCOPUS ID: 2-s2.0-85017516033 03/16/2017 18 Citations

Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017 6 Citations

Treatment of severe mucositis pain with oral ketamine mouthwash. (Shillingburg A, Kanate AS, Hamadani M, Wen S, Craig M, Cumpston A) Support Care Cancer 2017 Jul;25(7):2215-2219 PMID: 28190158 PMCID: PMC5500907 SCOPUS ID: 2-s2.0-85012134699 02/13/2017 20 Citations

Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Jethava Y, Guru Murthy GS, Hamadani M) Hematol Oncol Stem Cell Ther 2017 Jun;10(2):47-56 PMID: 28183681 SCOPUS ID: 2-s2.0-85012253423 02/12/2017 8 Citations

Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 SCOPUS ID: 2-s2.0-85013473580 02/06/2017 27 Citations

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 PMID: 28159578 SCOPUS ID: 2-s2.0-85011032026 02/06/2017 18 Citations

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. (Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W) Biol Blood Marrow Transplant 2017 May;23(5):767-775 PMID: 28115276 PMCID: PMC5590102 SCOPUS ID: 2-s2.0-85014101308 01/25/2017 42 Citations

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535 PMID: 28066928 SCOPUS ID: 2-s2.0-85009230369 01/10/2017 56 Citations

Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL). (Shah N, Rauenzahn S, Veltri L, Wen S, Craig M, Hamadani M, Kanate AS, Cumpston A) Bone Marrow Transplant 2017 Feb;52(2):321-322 PMID: 27892948 SCOPUS ID: 2-s2.0-84997822155 11/29/2016 2 Citations

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. (Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M) Am J Hematol 2017 Feb;92(2):161-170 PMID: 27880984 PMCID: PMC5549936 SCOPUS ID: 2-s2.0-85009832242 11/24/2016 56 Citations

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. (Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Feb;23(2):269-277 PMID: 27864161 PMCID: PMC5346183 SCOPUS ID: 2-s2.0-85008193410 11/20/2016 20 Citations

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 SCOPUS ID: 2-s2.0-85006371447 10/30/2016 16 Citations

Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN) Biol Blood Marrow Transplant 2016 Dec;22(12):2117-2125 PMID: 27660167 PMCID: PMC5116249 SCOPUS ID: 2-s2.0-85003030059 10/18/2016 80 Citations

Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66 PMID: 27742072 SCOPUS ID: 2-s2.0-84992187395 10/16/2016 6 Citations

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 Dec;16(12):672-678 PMID: 27660080 SCOPUS ID: 2-s2.0-84997605125 09/24/2016 7 Citations

Think outside the box: Acanthamoeba encephalitis following autologous haematopoietic stem cell transplantation. (Epperla N, Olteanu H, Hamadani M) Br J Haematol 2016 Dec;175(5):758 PMID: 27650173 SCOPUS ID: 2-s2.0-84988384116 09/22/2016 3 Citations

Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 SCOPUS ID: 2-s2.0-84991038636 09/07/2016 13 Citations

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers ME, Savani BN, Shaw BE) Bone Marrow Transplant 2017 Feb;52(2):173-182 PMID: 27548466 PMCID: PMC5288134 SCOPUS ID: 2-s2.0-84983515188 08/23/2016 53 Citations

Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 SCOPUS ID: 2-s2.0-84980370503 08/02/2016 5 Citations

Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. (Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A) Future Oncol 2016 Nov;12(22):2631-2642 PMID: 27381652 SCOPUS ID: 2-s2.0-84992179571 07/07/2016 15 Citations

Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 SCOPUS ID: 2-s2.0-84992043960 06/28/2016 7 Citations

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. (Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Cahn JY, Camitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soiffer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W) Cancer 2016 Oct;122(19):3005-3014 PMID: 27315441 PMCID: PMC5030151 SCOPUS ID: 2-s2.0-84978397912 06/18/2016 40 Citations

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 SCOPUS ID: 2-s2.0-84989838395 06/09/2016 189 Citations

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party) Biol Blood Marrow Transplant 2016 Aug;22(8):1493-1503 PMID: 27184625 PMCID: PMC4949101 SCOPUS ID: 2-s2.0-84981340623 05/18/2016 53 Citations

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 SCOPUS ID: 2-s2.0-84965053091 05/11/2016 15 Citations

Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. (Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A) Support Care Cancer 2016 Oct;24(10):4237-40 PMID: 27137211 SCOPUS ID: 2-s2.0-84965056679 05/04/2016 5 Citations

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. (Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C) Biol Blood Marrow Transplant 2016 Sep;22(9):1543-1551 PMID: 27131863 PMCID: PMC4981559 SCOPUS ID: 2-s2.0-84991255774 05/02/2016 38 Citations

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 Jul;174(2):235-48 PMID: 26989808 PMCID: PMC4940282 SCOPUS ID: 2-s2.0-84978080661 03/19/2016 104 Citations

Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. (Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA) Immunotherapy 2016;8(4):435-47 PMID: 26973125 SCOPUS ID: 2-s2.0-84962605020 03/15/2016 26 Citations

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. (Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W) Biol Blood Marrow Transplant 2016 Jun;22(6):1056-1064 PMID: 26964698 PMCID: PMC4877686 SCOPUS ID: 2-s2.0-84963595294 03/12/2016 25 Citations

Prospective, Controlled Study of Acyclovir Pharmacokinetics in Obese Patients. (Turner RB, Cumpston A, Sweet M, Briggs F, Slain D, Wen S, Craig M, Hamadani M, Petros W) Antimicrob Agents Chemother 2016 Jan 11;60(3):1830-3 PMID: 26824940 PMCID: PMC4775958 SCOPUS ID: 2-s2.0-84960387281 01/30/2016 15 Citations

Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. (El-Asmar J, Reljic T, Ayala E, Hamadani M, Nishihori T, Kumar A, Kharfan-Dabaja MA) Biol Blood Marrow Transplant 2016 May;22(5):802-14 PMID: 26713431 SCOPUS ID: 2-s2.0-84957648541 12/30/2015 38 Citations

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. (Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium) Am J Hematol 2016 Mar;91(3):322-9 PMID: 26701142 PMCID: PMC4764423 SCOPUS ID: 2-s2.0-84959153683 12/25/2015 63 Citations

Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. (Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolaños-Meade J, Hamadani M) Blood 2016 Feb 18;127(7):938-47 PMID: 26670632 PMCID: PMC4760094 SCOPUS ID: 2-s2.0-84959378642 12/17/2015 226 Citations

Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use. (Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS) Cytotherapy 2015 Dec;17(12):1785-92 PMID: 26475754 PMCID: PMC4700501 SCOPUS ID: 2-s2.0-84947584460 10/18/2015 28 Citations

Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer. (Nelson AA, Harrington AM, Kroft S, Dahar MA, Hamadani M, Dhakal B) Bone Marrow Transplant 2016 Feb;51(2):300-2 PMID: 26457913 SCOPUS ID: 2-s2.0-84956921726 10/13/2015 28 Citations

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. (Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M) Bone Marrow Transplant 2016 Jan;51(1):58-66 PMID: 26437062 PMCID: PMC4703480 SCOPUS ID: 2-s2.0-84953367337 10/06/2015 32 Citations

Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015

Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 PMID: 26422743 SCOPUS ID: 2-s2.0-84942932373 10/01/2015 30 Citations

Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherril B, Ruiz-Soto R, Kaye JA, Hamadani M) J Oncol Pharm Pract 2016 Oct;22(5):666-78 PMID: 26320127 SCOPUS ID: 2-s2.0-84981502122 09/01/2015 4 Citations

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. (Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A) Bone Marrow Transplant 2015 Dec;50(12):1513-8 PMID: 26301967 PMCID: PMC4548821 SCOPUS ID: 2-s2.0-84949085500 08/25/2015 31 Citations

Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044 SCOPUS ID: 2-s2.0-84944536944 08/19/2015 10 Citations

Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? (Epperla N, Fenske TS, Lazarus HM, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1393-404 PMID: 26281033 SCOPUS ID: 2-s2.0-84947047644 08/19/2015 8 Citations

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 PMID: 26253007 PMCID: PMC4639453 SCOPUS ID: 2-s2.0-84947494295 08/09/2015 47 Citations

A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. (Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1416-23 PMID: 26237164 PMCID: PMC4633349 SCOPUS ID: 2-s2.0-84947021369 08/04/2015 46 Citations

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. (Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee) Biol Blood Marrow Transplant 2015 Sep;21(9):1605-11 PMID: 25983043 PMCID: PMC4558181 SCOPUS ID: 2-s2.0-84938993122 05/20/2015 31 Citations

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. (Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W) Biol Blood Marrow Transplant 2015 Oct;21(10):1746-53 PMID: 25981509 PMCID: PMC4568162 SCOPUS ID: 2-s2.0-84941315276 05/20/2015 42 Citations

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. (Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS) Antimicrob Agents Chemother 2015 Aug;59(8):4424-8 PMID: 25987632 PMCID: PMC4505228 SCOPUS ID: 2-s2.0-84939863729 05/20/2015 55 Citations

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. (Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL) Bone Marrow Transplant 2015 Aug;50(8):1057-62 PMID: 25915806 PMCID: PMC4527880 SCOPUS ID: 2-s2.0-84938988030 04/29/2015 23 Citations

Secondary solid cancer screening following hematopoietic cell transplantation. (Inamoto Y, Shah NN, Savani BN, Shaw BE, Abraham AA, Ahmed IA, Akpek G, Atsuta Y, Baker KS, Basak GW, Bitan M, DeFilipp Z, Gregory TK, Greinix HT, Hamadani M, Hamilton BK, Hayashi RJ, Jacobsohn DA, Kamble RT, Kasow KA, Khera N, Lazarus HM, Malone AK, Lupo-Stanghellini MT, Margossian SP, Muffly LS, Norkin M, Ramanathan M, Salooja N, Schoemans H, Wingard JR, Wirk B, Wood WA, Yong A, Duncan CN, Flowers ME, Majhail NS) Bone Marrow Transplant 2015 Aug;50(8):1013-23 PMID: 25822223 PMCID: PMC4989866 SCOPUS ID: 2-s2.0-84938971140 03/31/2015 117 Citations

A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. (Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM) Clin Lymphoma Myeloma Leuk 2015 Jul;15(7):428-432.e2 PMID: 25776192 PMCID: PMC4484305 SCOPUS ID: 2-s2.0-84937521005 03/18/2015 68 Citations

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66 PMID: 25769794 SCOPUS ID: 2-s2.0-84930577739 03/15/2015 90 Citations

Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 SCOPUS ID: 2-s2.0-84926418285 01/27/2015 6 Citations

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. (Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2015 Mar;21(3):552-8 PMID: 25528388 PMCID: PMC4329042 SCOPUS ID: 2-s2.0-84922826985 12/22/2014 10 Citations

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-1512 PMID: 25456369 SCOPUS ID: 2-s2.0-84925230724 12/03/2014 243 Citations

Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. (Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):199-207 PMID: 25445467 SCOPUS ID: 2-s2.0-84925349629 12/03/2014 2 Citations

Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 SCOPUS ID: 2-s2.0-84930383567 11/12/2014 9 Citations

Autologous hematopoietic cell transplantation: an update for clinicians. (Hamadani M) Ann Med 2014 Dec;46(8):619-32 PMID: 25211470 SCOPUS ID: 2-s2.0-84919394670 09/12/2014 13 Citations

Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 SCOPUS ID: 2-s2.0-84912142377 08/12/2014 23 Citations

Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 SCOPUS ID: 2-s2.0-84908019168 07/11/2014 105 Citations

Reply to S. Fuji et al. (Hamadani M, Vos JA, Craig MD) J Clin Oncol 2014 Jun 10;32(17):1860-1 PMID: 24799471 SCOPUS ID: 2-s2.0-84905823897 05/07/2014

Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 SCOPUS ID: 2-s2.0-84900867182 05/03/2014 9 Citations

Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. (Kanate AS, Pasquini MC, Hari PN, Hamadani M) World J Stem Cells 2014 Apr 26;6(2):69-81 PMID: 24772235 PMCID: PMC3999783 04/29/2014

Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. (McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ) Biol Blood Marrow Transplant 2014 Jul;20(7):960-8 PMID: 24641829 PMCID: PMC4057955 SCOPUS ID: 2-s2.0-84902120179 03/20/2014 32 Citations

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. (Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W) Biol Blood Marrow Transplant 2014 Jul;20(7):951-9 PMID: 24641828 PMCID: PMC4060436 SCOPUS ID: 2-s2.0-84902084890 03/20/2014 26 Citations

Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. (Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA) Semin Hematol 2014 Jan;51(1):73-86 PMID: 24468319 SCOPUS ID: 2-s2.0-84892844240 01/29/2014 9 Citations

Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. (Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I) Biol Blood Marrow Transplant 2014 May;20(5):646-54 PMID: 24462982 SCOPUS ID: 2-s2.0-84897957278 01/28/2014 23 Citations

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN) Bone Marrow Transplant 2014 May;49(5):599-606 PMID: 24442246 SCOPUS ID: 2-s2.0-84900310741 01/21/2014 26 Citations

Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? (Hamadani M) Biol Blood Marrow Transplant 2014 Mar;20(3):292-4 PMID: 24394802 SCOPUS ID: 2-s2.0-84896860237 01/08/2014 2 Citations

Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. (Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS) Biol Blood Marrow Transplant 2014 Mar;20(3):415-20 PMID: 24361913 PMCID: PMC4557764 SCOPUS ID: 2-s2.0-84896859987 12/24/2013 16 Citations

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 SCOPUS ID: 2-s2.0-84897020212 12/18/2013 111 Citations

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. (Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD) J Clin Oncol 2013 Dec 10;31(35):4416-23 PMID: 24166529 PMCID: PMC3842909 SCOPUS ID: 2-s2.0-84894066201 10/30/2013 30 Citations

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97 PMID: 24161923 PMCID: PMC3886623 SCOPUS ID: 2-s2.0-84890911661 10/29/2013 110 Citations

Limited utility of surveillance imaging for detecting disease relapse in patients with non-Hodgkin lymphoma in first complete remission. (Truong Q, Shah N, Knestrick M, Curley B, Hu Y, Craig M, Hamadani M) Clin Lymphoma Myeloma Leuk 2014 Feb;14(1):50-5 PMID: 24119465 SCOPUS ID: 2-s2.0-84892799685 10/15/2013 25 Citations

Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. (Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A) Ann Hematol 2014 Apr;93(4):677-82 PMID: 24097085 SCOPUS ID: 2-s2.0-84896351806 10/08/2013 19 Citations

Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas. (Hamadani M, Kanate AS) Community Oncology Hamadani M., Kanate AS.: “Dawn of a new era: targeting the B-cell receptor signaling pathway to conquer B-cell lymphomas.” Community Oncology. 2013 October;10(10):279-281 10/01/2013

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. (Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W) Blood 2013 Dec 05;122(24):3863-70 PMID: 24065243 PMCID: PMC3854108 SCOPUS ID: 2-s2.0-84891072099 09/26/2013 137 Citations

Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A) Br J Haematol 2013 Nov;163(3):315-25 PMID: 24033280 SCOPUS ID: 2-s2.0-84885418745 09/17/2013 31 Citations

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. (Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M) J Clin Apher 2013 Oct;28(5):359-67 PMID: 23765597 SCOPUS ID: 2-s2.0-84885958621 06/15/2013 25 Citations

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. (Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M) Bone Marrow Res 2013;2013:414959 PMID: 23691325 PMCID: PMC3652129 05/22/2013

Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. (Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1133-5 PMID: 23635452 SCOPUS ID: 2-s2.0-84879370980 05/03/2013 4 Citations

Management strategies for follicular lymphoma patients in remission after modern frontline chemoimmunotherapies. (Chaudhary L, Hamadani M) Journal of Blood Disorders & Transfusion Chaudhary L, Hamadani M (2012) Management Strategies for Follicular Lymphoma patients in Remission after Modern Frontline Chemoimmunotherapies. J Blood Disorders Transf 3:e105 05/01/2013

Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M) Biol Blood Marrow Transplant 2013 Sep;19(9):1288-300 PMID: 23618718 SCOPUS ID: 2-s2.0-84884209890 04/27/2013 10 Citations

Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? (Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M) Bone Marrow Transplant 2013 Nov;48(12):1489-96 PMID: 23584438 SCOPUS ID: 2-s2.0-84889590282 04/16/2013 9 Citations

Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. (Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M) Bone Marrow Transplant 2013 Oct;48(10):1279-84 PMID: 23584435 SCOPUS ID: 2-s2.0-84885599846 04/16/2013 43 Citations

Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. (Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1006-12 PMID: 23396213 SCOPUS ID: 2-s2.0-84879409907 02/12/2013 71 Citations

Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 SCOPUS ID: 2-s2.0-84876298990 02/06/2013 69 Citations

Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 SCOPUS ID: 2-s2.0-84875481784 01/22/2013 66 Citations

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A) J Hematol Oncol 2013 Jan 04;6:2 PMID: 23289975 PMCID: PMC3548722 SCOPUS ID: 2-s2.0-84871732121 01/08/2013 40 Citations

Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit. (Cumpston A, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR) Transpl Infect Dis 2013 Apr;15(2):142-9 PMID: 23279656 SCOPUS ID: 2-s2.0-84875931709 01/03/2013 20 Citations

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 SCOPUS ID: 2-s2.0-84872527502 12/04/2012 28 Citations

Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma. (Kanate AS, Kharfan-Dabaja MA, Hamadani M) Bone Marrow Res 2012;2012:897215 PMID: 23097707 PMCID: PMC3477524 10/26/2012

Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis. (Ross AL, Slain D, Cumpston A, Bryant AM, Hamadani M, Craig M) Int J Antimicrob Agents 2012 Dec;40(6):557-61 PMID: 23068599 SCOPUS ID: 2-s2.0-84869502368 10/17/2012 14 Citations

Rituximab maintenance versus retreatment in follicular lymphoma. (Palla AR, Hamadani M) Hematol Oncol 2013 Dec;31(4):171-8 PMID: 23044794 SCOPUS ID: 2-s2.0-84889100671 10/10/2012 5 Citations

Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? (Hamadani M) Bone Marrow Transplant 2013 Aug;48(8):1013-21 PMID: 23000653 SCOPUS ID: 2-s2.0-84881373592 09/25/2012 14 Citations

Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit. (Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M) Am J Infect Control 2012 Dec;40(10):931-4 PMID: 22575286 SCOPUS ID: 2-s2.0-84870417336 05/12/2012 58 Citations

Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. (Awan FT, Kochuparambil ST, Deremer D, Cumpston A, Craig M, Jillella A, Hamadani M) J Oncol 2012;2012:931071 PMID: 22570654 PMCID: PMC3335320 SCOPUS ID: 2-s2.0-84861042264 05/10/2012 13 Citations

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W) Biol Blood Marrow Transplant 2012 Sep;18(9):1446-54 PMID: 22449610 PMCID: PMC3499973 SCOPUS ID: 2-s2.0-84865198731 03/28/2012 16 Citations

Regulation of acute graft-versus-host disease by microRNA-155. (Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon R) Blood 2012 May 17;119(20):4786-97 PMID: 22408260 PMCID: PMC3367879 SCOPUS ID: 2-s2.0-84861209261 03/13/2012 123 Citations

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. (Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F) Biol Blood Marrow Transplant 2012 Jul;18(7):1128-35 PMID: 22248715 SCOPUS ID: 2-s2.0-84862147136 01/18/2012 60 Citations

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. (Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M) Hematol Oncol Stem Cell Ther 2011;4(4):149-56 PMID: 22198185 SCOPUS ID: 2-s2.0-84855498804 12/27/2011 6 Citations

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Mohty M, Kharfan-Dabaja MA) Cancer Control 2011 Oct;18(4):237-45 PMID: 21976242 SCOPUS ID: 2-s2.0-80052973754 10/07/2011 28 Citations

CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells. (Liu K, Anthony BA, Yearsly MM, Hamadani M, Gaughan A, Wang JJ, Devine SM, Hadley GA) PLoS One 2011;6(7):e21968 PMID: 21779359 PMCID: PMC3136479 SCOPUS ID: 2-s2.0-79960308653 07/23/2011 10 Citations

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88 PMID: 21690560 PMCID: PMC3158724 SCOPUS ID: 2-s2.0-80051878404 06/22/2011 65 Citations

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. (Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM) Hematol Oncol 2011 Dec;29(4):202-10 PMID: 21360728 PMCID: PMC3557914 SCOPUS ID: 2-s2.0-80052987567 03/02/2011 14 Citations

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. (Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M) Bone Marrow Transplant 2012 Jan;47(1):146-8 PMID: 21358681 SCOPUS ID: 2-s2.0-84855736330 03/02/2011 5 Citations

The evolving role of statins in hematopoietic stem and progenitor cell transplantation. (Hamadani M, Craig MD, Gibson LF, Remick SC) Am J Blood Res 2011;1(1):57-64 PMID: 22432066 PMCID: PMC3301410 01/01/2011

Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. (Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA) J Clin Oncol 2010 Nov 01;28(31):e629-32 PMID: 20733121 SCOPUS ID: 2-s2.0-77957820874 08/25/2010 30 Citations

How we approach patient evaluation for hematopoietic stem cell transplantation. (Hamadani M, Craig M, Awan FT, Devine SM) Bone Marrow Transplant 2010 Aug;45(8):1259-68 PMID: 20479713 SCOPUS ID: 2-s2.0-77955583042 05/19/2010 59 Citations

Malignant thymoma with immunodeficiency (Good syndrome) associated with mucormycosis. (Hamadani M, Awan F, Villalona-Calero MA) Am J Clin Oncol 2010 Feb;33(1):109 PMID: 20139744 SCOPUS ID: 2-s2.0-77649319481 02/09/2010 5 Citations

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. (Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM) Leuk Lymphoma 2010 Feb;51(2):243-51 PMID: 20038230 PMCID: PMC3557809 SCOPUS ID: 2-s2.0-76349087847 12/30/2009 15 Citations

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 Nov;15(11):1422-30 PMID: 19822302 PMCID: PMC3953136 SCOPUS ID: 2-s2.0-70350621059 10/14/2009 74 Citations

Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia. (Pant S, Hamadani M, Dodds AJ, Szer J, Crilley PA, Stevenson D, Phillips G, Elder P, Nivison-Smith I, Avalos BR, Penza S, Topolsky D, Sobecks R, Kalaycio M, Bolwell BJ, Copelan EA) Br J Haematol 2010 Feb;148(4):623-6 PMID: 19821825 SCOPUS ID: 2-s2.0-75149135589 10/14/2009 3 Citations

Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. (Hamadani M, Devine SM) Blood 2009 Sep 17;114(12):2564-6 PMID: 19762505 SCOPUS ID: 2-s2.0-70350499490 09/19/2009 16 Citations

Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. (Hamadani M, Awan FT) Hematol Oncol 2010 Mar;28(1):3-12 PMID: 19645073 SCOPUS ID: 2-s2.0-77950870037 08/01/2009 9 Citations

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. (Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 May;15(5):547-53 PMID: 19361746 PMCID: PMC3953134 SCOPUS ID: 2-s2.0-63749116090 04/14/2009 39 Citations

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. (Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC) Leuk Lymphoma 2009 Mar;50(3):349-56 PMID: 19263294 PMCID: PMC3695225 SCOPUS ID: 2-s2.0-67650876387 03/06/2009 5 Citations

Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Blum W) Clinical Leukemia Hamadani M., Blum W.: “Role of hematopoietic stem cell transplantation in adults with acute myeloid leukemia.” Clinical Leukemia. 2009 February;3(1):47-57 02/01/2009

Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM) Leuk Lymphoma 2008 Oct;49(10):1893-8 PMID: 18949613 SCOPUS ID: 2-s2.0-55049125260 10/25/2008 9 Citations

Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? (Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M) J Clin Oncol 2008 Nov 01;26(31):5134-6; author reply 5136-7 PMID: 18838697 SCOPUS ID: 2-s2.0-55549116005 10/08/2008 60 Citations

High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM) Eur J Haematol 2008 Dec;81(6):425-31 PMID: 18774954 SCOPUS ID: 2-s2.0-56649106241 09/09/2008 27 Citations

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM) Biol Blood Marrow Transplant 2008 Jul;14(7):783-9 PMID: 18541197 PMCID: PMC4100722 SCOPUS ID: 2-s2.0-44649176508 06/11/2008 48 Citations

Review: isolated skeletal involvement in hairy cell leukemia. (Hamadani M, Kraut EH) Clin Adv Hematol Oncol 2008 Apr;6(4):294-6 PMID: 18496496 SCOPUS ID: 2-s2.0-46449106770 05/23/2008 1 Citation

Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Awan FT, Copelan EA) Biol Blood Marrow Transplant 2008 May;14(5):556-67 PMID: 18410898 SCOPUS ID: 2-s2.0-41949142667 04/16/2008 37 Citations

The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. (Hamadani M, Awan FT, Devine SM) Blood 2008 Apr 01;111(7):3901-2 PMID: 18362217 SCOPUS ID: 2-s2.0-43549086236 03/26/2008 41 Citations

Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM) Biol Blood Marrow Transplant 2008 Apr;14(4):480-3 PMID: 18342792 SCOPUS ID: 2-s2.0-40649087167 03/18/2008 34 Citations

The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. (Hamadani M, Hade E, Benson DM Jr, Hofmeister CC) Biol Blood Marrow Transplant 2008 Mar;14(3):351-2 PMID: 18275902 SCOPUS ID: 2-s2.0-38949113627 02/16/2008 7 Citations

False-negative PET scan with bronchioloalveolar carcinoma: an important diagnostic caveat. (Awab A, Hamadani M, Peyton M, Brown B) Am J Med Sci 2007 Oct;334(4):311-3 PMID: 18030191 SCOPUS ID: 2-s2.0-38449104846 11/22/2007 9 Citations

An unusual etiology of chest pain. (Rashid A, Afaq A, Hamadani M, Warraich J, Hennebry T) J Okla State Med Assoc 2007 Sep;100(9):352-3 PMID: 18020040 SCOPUS ID: 2-s2.0-38449114409 11/21/2007

CD4+ CD56+ haematodermic tumour (plasmacytoid dendritic cell neoplasm). (Hamadani M, Magro CM, Porcu P) Br J Haematol 2008 Jan;140(2):122 PMID: 17991297 SCOPUS ID: 2-s2.0-37249053873 11/10/2007 2 Citations

Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? (Hamadani M, Chaudhary L, Awan FT, Khan JK, Kojouri K, Ozer H, Tfayli A) J Oncol Pharm Pract 2007 Jun;13(2):69-75 PMID: 17873106 SCOPUS ID: 2-s2.0-34548623153 09/18/2007 24 Citations

Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. (Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr) Am J Hematol 2007 Dec;82(12):1120-1 PMID: 17654679 SCOPUS ID: 2-s2.0-36749033711 07/27/2007 2 Citations

Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. (Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM) Transpl Infect Dis 2008 Feb;10(1):24-6 PMID: 17651365 SCOPUS ID: 2-s2.0-38649099975 07/27/2007 17 Citations

Gastrointestinal chronic graft-versus-host disease: management options. (Awan F, Hamadani M) J Oncol Pharm Pract 2007 Mar;13(1):49-51 PMID: 17621568 SCOPUS ID: 2-s2.0-34250202254 07/11/2007 1 Citation

Thalidomide-induced fulminant hepatic failure. (Hamadani M, Benson DM Jr, Copelan EA) Mayo Clin Proc 2007 May;82(5):638 PMID: 17493431 SCOPUS ID: 2-s2.0-34248174502 05/12/2007 10 Citations

Paraneoplastic Sweet's syndrome and the pathergy phenomenon. (Awan F, Hamadani M, Devine S) Ann Hematol 2007 Aug;86(8):613-4 PMID: 17468870 SCOPUS ID: 2-s2.0-34347390449 05/01/2007 14 Citations

Gastroparesis. (Ali T, Hasan M, Hamadani M, Harty RF) South Med J 2007 Mar;100(3):281-6 PMID: 17396732 SCOPUS ID: 2-s2.0-34247626451 04/03/2007 26 Citations

Limitations of Sokal score in patients with chronic myeloid leukemia. (Hamadani SM, Chaudhary L) J Coll Physicians Surg Pak 2007 Mar;17(3):182; author reply 182 PMID: 17374310 SCOPUS ID: 2-s2.0-34548414552 03/22/2007

Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. (Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC) Bone Marrow Transplant 2007 Feb;39(4):249-51 PMID: 17290281 SCOPUS ID: 2-s2.0-33846965585 02/10/2007 19 Citations

McCune-Albright syndrome. (Hamadani M, Chaudhary L) Med J Aust 2006 Dec 4-18;185(11-12):597 PMID: 17181499 SCOPUS ID: 2-s2.0-33846109352 12/22/2006 1 Citation

Role of thiamine in managing ifosfamide-induced encephalopathy. (Hamadani M, Awan F) J Oncol Pharm Pract 2006 Dec;12(4):237-9 PMID: 17156595 SCOPUS ID: 2-s2.0-33846208731 12/13/2006 39 Citations

Early detection of digitalis-induced nonocclusive mesenteric ischemia using Doppler ultrasonography. (Awab A, Hamadani M, Saya S, Whitsett T) South Med J 2006 Oct;99(10):1142 PMID: 17100040 SCOPUS ID: 2-s2.0-33750349117 11/15/2006 2 Citations

Infected atrial myxoma. (Awab A, Hamadani M, Sud B, Voskuhl GW) Med J Aust 2006 Sep 18;185(6):332 PMID: 16999677 SCOPUS ID: 2-s2.0-33749457407 09/27/2006 4 Citations

Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. (Hamadani M, Awab A, Chaudhary L, Tfayli A) J Oncol Pharm Pract 2006 Jun;12(2):67-8 PMID: 16984743 SCOPUS ID: 2-s2.0-34248191058 09/21/2006 3 Citations

Role of intra-arterial steroid administration in the management of steroid-refractory acute gastrointestinal graft-versus-host disease. (Tfayli A, Selby G, Maqbool F, Bierbaum W, Hamadani M) Am J Hematol 2006 Dec;81(12):959-62 PMID: 16924649 SCOPUS ID: 2-s2.0-33845251157 08/23/2006 11 Citations

Fibrous dysplasia protuberans in a patient with McCune-Albright syndrome. (Hamadani M, Awab A, Rashid A, Ali T, Brown B) J Coll Physicians Surg Pak 2006 May;16(5):376-7 PMID: 16756788 SCOPUS ID: 2-s2.0-36048942994 06/08/2006 6 Citations

Marginal zone B-cell lymphoma of the uterus: a case report and review of the literature. (Hamadani M, Kharfan-Dabaja M, Kamble R, Kern W, Ozer H) J Okla State Med Assoc 2006 Apr;99(4):154-6 PMID: 16703935 SCOPUS ID: 2-s2.0-33745119009 05/18/2006 10 Citations

Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. (Kamble RT, Hamadani M, Selby GB) J Antimicrob Chemother 2006 Apr;57(4):795-6 PMID: 16476723 SCOPUS ID: 2-s2.0-33645122129 02/16/2006 1 Citation

Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. (Kamble RT, Hamadani M, Selby GB) Biol Blood Marrow Transplant 2006 Jan;12(1):111-2 PMID: 16399575 SCOPUS ID: 2-s2.0-29844447198 01/10/2006 2 Citations

Granulocytic sarcoma manifesting as multiple skeletal lesions. (Hamadani M, Tfayli A, Sethi S, Awab A, Hamdani N) Am J Med Sci 2005 Sep;330(3):139-43 PMID: 16174998 SCOPUS ID: 2-s2.0-25444458899 09/22/2005 13 Citations

Last update: 01/10/2024

© 2024 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Mehdi H. Hamadani MD

Professor

Publications (384)